[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mitochondrial-dysfunction\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mitochondrial-dysfunction":32},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,53],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":33,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":4},"100652393","mitochondrial-intervention-for-resilience-in-older-adults-with-coenzyme-q10-100652393",false,"NCT07772336","MItochondrial Intervention for Resilience in Older Adults With Coenzyme Q10","Mitochondrial Intervention for Resilience in Older Adults With Coenzyme Q10","MIRO-Q","Inclusion Criteria\n\n* Age 65 years or older.\n* Community-dwelling older adult.\n* Presence of signs of reduced biological resilience or prefrailty, defined by meeting at least one of the following criteria:\n\n  * Prefrailty according to the Fried frailty phenotype, defined as the presence of 1-2 of the following criteria: unintentional weight loss, self-reported exhaustion, reduced physical activity, slow walking speed, or reduced handgrip strength; or\n  * Reduced physical performance, defined as a Short Physical Performance Battery (SPPB) score of ≤9; or\n  * Increased functional vulnerability, defined as a Clinical Frailty Scale (CFS) score of ≥4.\n* Ability to understand the study procedures and comply with the study protocol.\n* Ability and willingness to provide written informed consent before participation.\n\nExclusion Criteria\n\n* Established frailty with severe functional impairment that would interfere with study participation or outcome assessment.\n* Advanced dementia or cognitive impairment preventing informed consent or reliable participation in study assessments.\n* Active malignant disease or ongoing cancer treatment.\n* Acute inflammatory disease or acute infection at the time of enrollment.\n* Acute or unstable medical condition that could substantially affect functional performance, cognitive assessment, or the safety of the intervention.\n* Any medical condition considered by the investigator to make participation inappropriate or unsafe.\n* Current use of CoQ10 supplementation at a dose that could interfere with assessment of the study intervention, unless discontinued for the predefined washout period.\n* Known hypersensitivity or intolerance to CoQ10 or any component of the study product.\n* Participation in another interventional clinical trial that could affect the outcomes of the present study.",true,"ALL","65 Years",{"count":21,"type":22},100,"ESTIMATED","INTERVENTIONAL",[25],"NA","This randomized, double-blind, placebo-controlled clinical trial will investigate whether 10 weeks of CoQ10 supplementation can improve biological resilience and functional health in community-dwelling adults aged 65 years or older with signs of reduced biological resilience or prefrailty.\n\nParticipants will be randomly assigned in a 1:1 ratio to receive either 200 mg of CoQ10 daily or matching placebo for 10 weeks. The study will assess the effects of CoQ10 supplementation on mitochondrial functional resilience, chronic low-grade inflammation, metabolic health, physical performance, cognitive function, and objective measures of skin aging.\n\nThe study will also investigate whether baseline biological and functional characteristics can identify individuals who are more likely to benefit from CoQ10 supplementation. An exploratory aim is to develop a multidimensional composite index of biological resilience integrating molecular, biochemical, functional, and clinical measures of aging.\n\nThe study will provide evidence on whether a mitochondria-targeted intervention with CoQ10 may represent a potential strategy for improving functional resilience and reducing features of prefrailty in older adults.",[28,29,30,31,32],"Frailty","Aging","Mitochondria Health","Skin Aging","Mitochondrial Dysfunction",[34,35,36,37,38,39,40],"frailty","aging","older adults","Coenzyme Q10","mitochondrial dysfunction","geroscience","functional aging","NOT_YET_RECRUITING","2026-08-13",{"date":44,"type":45},"2026-08-19","ACTUAL",{"date":47,"type":22},"2026-09",{"date":49,"type":22},"2027-02",{"name":51,"class":52},"University Medical Centre Ljubljana","OTHER",{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":59,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":18,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":23,"phases":64,"briefSummary":65,"conditions":66,"keywords":71,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":88},"100564641","the-effect-of-the-nutraceutical----epicatechin-on-myosteatosis-in-patients-with-advanced-ckd-100564641","NCT06631820","The Effect of the Nutraceutical (-)- Epicatechin on Myosteatosis in Patients With Advanced CKD","The Effect of the Nutraceutical (-)- Epicatechin on Myosteatosis in Patients With Advanced CKD: a Pilot Study (EPIC-CKD)","EPIC-CKD","Inclusion Criteria:\n\n* estimated glomerular filtration rate (eGFR) \\\u003C 29 ml\u002Fmin\u002F1.75m2\n* no chronic or acute known liver disease\n* not intended to initiate renal replacement therapy treatment in the next 4 months according to nephrologist clinical judgment\n\nExclusion Criteria:\n\n* signs of active infection\n* acute vasculitis\n* type 1 diabetes\n* use of steroids medication\n* transplanted patients\n* patients with deambulatory impairment (wheelchair users, bed rest)\n* patients on compassionate care for the end of life\n* with advanced neurological disorders\n* with cognitive impairments\n* with active cancer diagnosis\n* participation in another interventional trial.","60 Years",{"count":63,"type":22},10,[25],"Some foods have components that can prevent and treat some diseases and provide beneficial effects for health. These components naturally occurring in foods are called nutraceuticals. Recently, it was found that Epicatechin, which is a kind of nutraceutical from the Catechin's family naturally occurring in green tea and cocoa, has positive effects on muscle mass and strength of people with chronic diseases.\n\nPeople with chronic kidney disease often present muscle loss and lack of strength that are not easily treated with regular diet and physical activity. We here propose a study where 10 individuals with chronic kidney disease will receive a dose of Epicatechin for 8 weeks and we aim to test if Epicatechin improves general muscle health. Based on what is known, we expect to see an increase in muscle mass and strength.\n\nThe dose of Epicatechin provided (100 mg\u002Fday) is safe, since it is much lower than the dose usually available in supplements. In addition, this is the form naturally present in green tea and cocoa and in similar amounts. Subjects participating in the study will be evaluated for muscle mass and strength three times during the study. Muscle mass and muscle quality will be evaluated by ultrasound and magnetic resonance imaging. The participants will also perform some tests like walking in a corridor and seating and standing from a chair to measure their strength and performance. Adverse side effects will be monitored via telephone, and safety will be assessed by monthly blood tests that will evaluate liver and kidney function. If this study shows that Epicatechin can promote muscle growth and strength, it will positively affect patients with chronic kidney disease that might benefit of a natural substance from food to improve muscle health.",[67,68,32,69,70],"Chronic Kidney Disease(CKD)","Myosteatosis","Muscle Function","Muscle Mass",[72,73,74,75,38,76,77],"myosteatosis","epicatechin","nutraceuticals","chronic kidney disease","muscle regeneration","muscle function","RECRUITING","2025-07-07",{"date":81,"type":45},"2025-07-10",{"date":83,"type":45},"2025-01-17",{"date":85,"type":22},"2026-10",{"name":87,"class":52},"Karolinska Institutet",1]